Medpage Today: SGLT2 Inhibitor Eases Symptoms for HFpEF Patients

Symptoms of heart failure with preserved ejection fraction (HFpEF) improved with dapagliflozin (Farxiga) therapy, the PRESERVED-HF trial showed.

After 12 weeks of treatment, Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary scores were 5.8 points higher for patients randomized to the SGLT2 inhibitor over placebo (P=0.001), bringing scores from the low 60s at baseline to the high 60s, reported Mikhail Kosiborod, MD, of Saint Luke's Mid America Heart Institute in Kansas City, Missouri.

"The treatment effect was large, clinically meaningful, and statistically significant," Kosiborod concluded of the 324-person study during a late-breaking trial session at the Heart Failure Society of America (HFSA) meeting held both virtually and in Denver. He mentioned that the study manuscript is in press at Nature Medicine.

Read the rest of the Medpage Today article: SGLT2 Inhibitor Eases Symptoms for HFpEF Patients

Related Content

Saint Luke's Mid America Heart Institute
Oct. 28, 2021

PRESERVED-HF trial findings on the substantial impact of dapagliflozin in individuals with heart failure with preserved ejection fraction (HFpEF) published in Nature Medicine
The findings of the PRESERVED-HF trial, offering potential new hope for people struggling with heart failure with preserved ejection fraction (HFpEF), are published in the journal, Nature Medicine.
Aug. 19, 2021

Managed Healthcare Executive: Mavacamten, First-in-Class Therapy, May Soon Be Available for Hypertrophic Cardiomyopathy
A therapy on the horizon could be the first to specifically treat the underlying cause of hypertrophic cardiomyopathy.